Photo of Aditya  Bardia, MBBS, MPH

Aditya Bardia, MBBS, MPH


Accepting New Patients





Centers & Specialties

Cancer Center

Clinical Interests
  • Breast cancer
  • Targeted therapies
Medical Education
  • MBBS, All India Institute of Medical Sciences
  • MPH, University of Iowa College of Public Health
  • Residency, All India Institute of Medical Sciences|Residency, Mayo Clinic
  • Fellowship, The Johns Hopkins Hospital
Board Certifications
  • Internal Medicine
  • Medical Oncology
  • Boston: Massachusetts General Hospital
Patient Gateway
Yes, learn more
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Centene/Celticare
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • Medicaid
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
Patient Age Group

Edit Profile


Dr. Bardia is a board-certified medical oncologist interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with breast cancer. The accurate identification of target is crucial for success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor genotyping as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection, and real-time monitoring of breast cancer. In collaboration the CTC center and Haber lab, his research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition, and provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer. Dr. Bardia is the principal investigator of clinical trials investigating the role of targeted therapy combinations for breast cancer. Dr. Bardia is the recipient of Young Investigator Award from the ASCO Conquer Cancer Foundation.

Edit Profile

Research & Publications


View my most recent publications at PubMed

Selected Publications
  1. Bardia A, Hartmann LC, et al. Leisure time physical activity & risk of postmenopausal breast cancer. Arch Intern Med. 2006;166:2478-83.
  2. Bardia A, Barton DL, et al. Efficacy of complementary & alternative medicine therapies in relieving cancer pain: Systematic Review. J Clin Oncol. 2006;24:5457-64.
  3. Bardia A, Ebbert JO, et al. Association of aspirin & other NSAID use with cancer incidence and mortality among post menopausal women. J Natl Cancer Inst. 2007;99(11):881-9.
  4. Bardia A, Stearns V. Personal Breast. Breast Cancer Res Treat. Editorial. 2010;120(2):437-9.
  5. Bardia A, Stearns V. Personalized Tamoxifen. Clin Cancer Res. Editorial. 2010;16(17):4308-10.

Edit Profile

News & Events


55 Fruit Street
Boston MA, 02114-2696
Phone: 617-724-4000617-643-0744
Fax: 617-643-0589

Edit Profile

Back to Top